- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05181618
A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis (Beyond ABR)
A Multicenter, Open-Label Phase IV Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes, in Participants Aged ≥13 and <70 Years With Severe or Moderate Hemophilia A Without FVIII Inhibitors on Emicizumab Prophylaxis
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Reference Study ID Number: MO42623 https://forpatients.roche.com/
- Phone Number: 888-662-6728 (U.S. Only)
- Email: global-roche-genentech-trials@gene.com
Study Locations
-
-
SP
-
Campinas, SP, Brazil, 13083-878
- Hospital das Clinicas - UNICAMP; Hemoterapia
-
Ribeirao Preto, SP, Brazil, 14051-140
- Hospital das Clínicas Faculdades Médicas de Ribeirão Preto
-
-
-
-
Ontario
-
Hamilton, Ontario, Canada, L9H 2B7
- Hamilton Health Sciences Corporation
-
-
-
-
-
Berlin, Germany, 13353
- Charité Universitätsklinikum Berlin; Klinik f. Pädiatrie - Onkologie und Hämatologie
-
Bonn, Germany, 53127
- Universitätsklinikum Bonn; Institut für Experimentelle Hämatologie und Transfusionsmedizin
-
-
-
-
-
Budapest, Hungary, 1134
- Észak-Pesti Centrumkórház - Honvédkórház; Országos Hemofília Központ
-
-
-
-
Campania
-
Napoli, Campania, Italy, 80131
- AOU Federico II; Medicina Clinica Chirurgia Centro Emocoaugulopatie e Emofilia
-
-
Lazio
-
Roma, Lazio, Italy, 00168
- Policlinico Univ. A. Gemelli; Polo di Scienze Oncologiche ed Ematologiche
-
-
Lombardia
-
Milano, Lombardia, Italy, 20122
- IRCCS Ca' Granda Ospedale Maggiore Policlinico; Centro Emofilia e Trombosi "Angelo Bianchi e Bonomi"
-
-
Toscana
-
Firenze, Toscana, Italy, 50134
- AOU Careggi; SOD Malattie Emorragiche
-
-
-
-
-
Rabat, Morocco, 10090
- Hôpital d'enfants de Rabat - Service d'hémato-oncologie pédiatrique
-
-
-
-
-
Belgrade, Serbia, 11000
- University Clinical Centre of Serbia; Clinic of Hematology
-
-
-
-
-
Barcelona, Spain, 08025
- Hospital de la Santa Creu i Sant Pau; Servicio de Hematologia
-
Barcelona, Spain, 08035
- Hospital Universitario Vall de Hebron; Unidad de Hemofília
-
Madrid, Spain, 28046
- Hospital Universitario la Paz; Servicio de Hematologia
-
Malaga, Spain, 29010
- Hospital Regional Universitario Carlos Haya; Servicio de Hematologia
-
-
LA Coruña
-
La Coruna, LA Coruña, Spain, 15006
- Complejo Hospitalario Universitario A Coruña (CHUAC); Servicio de Hematologia
-
-
-
-
-
Sousse, Tunisia, 4000
- CHU Farhat Hached; Service d'hématologie
-
Tunis, Tunisia
- Aziza Othmana Hospital; Haemophilia Center
-
-
-
-
-
Ankara, Turkey, 06100
- Gazi Universitesi Tip Fakultesi; Pediatric Neurology
-
Antalya, Turkey, 07059
- Akdeniz Uni School of Medicine; Hematology
-
Istanbul, Turkey, 34098
- Istanbul University Cerrahpasa Medical Faculty; Hematology Department
-
Izmir, Turkey, 35100
- Ege Uni Medical School; Hematology
-
-
-
-
-
London, United Kingdom, SE1 7EH
- St Thomas Westminster
-
Manchester, United Kingdom, M13 9WL
- Manchester University NHS Foundation Trust (MFT)
-
-
-
-
California
-
Los Angeles, California, United States, 90007
- Orthopaedic Institute for Children
-
-
Florida
-
Coral Gables, Florida, United States, 33146
- University of Miami
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Oklahoma Children's Hospital ? Jimmy Everest Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of severe congenital hemophilia A (intrinsic factor VIII [FVIII] level <1%) or moderate congenital hemophilia A (intrinsic FVIII level ≤5%) if previously prescribed prophylaxis
- A negative test for FVIII inhibitor (i.e., <0.6 Bethesda Units) during screening period
- No history of FVIII inhibitory antibodies (<0.6 BU/mL using the Bethesda assay) in the last 5 years. Participants who completed successful immune tolerance induction (ITI) at least 5 years before screening are eligible, provided they have had no evidence of inhibitor recurrence (permanent or temporary) as may be indicated by detection of an inhibitor, FVIII half-life <6 hours, or FVIII recovery <66% since completing ITI
- Participants who were on standard FVIII prophylaxis, defined as the regular administration of FVIII to prevent bleeding, for at least the last 24 weeks, can be enrolled regardless of the number of bleeds during this period
- Adequate hematologic, hepatic and renal function
- For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception during the treatment period and for at least 24 weeks after the final dose of emicizumab
Exclusion Criteria:
- Inherited or acquired bleeding disorder other than severe congenital hemophilia A (intrinsic FVIII level <1%) or moderate congenital hemophilia A (intrinsic FVIII level ≤5%) without FVIII inhibitors who were previously prescribed prophylaxis for at least 24 weeks
- Participants who have previously received emicizumab prophylaxis
- Participants that plan to have joint replacement, joint procedure, synovectomy or synoviorthesis at screening
- Participants who had joint replacement, joint procedure, synovectomy or synoviorthesis: Less than 2 years ago; OR, More than 3 years ago and are still experiencing pain in the joint. For participants who had joint replacement, joint procedure, synovectomy or synoviorthesis more than 2 years ago who are not experiencing pain in the joint(s), the participant may be enrolled but the specific joint(s) in which the procedure was conducted will be excluded from the study
- Participants who have conditions other than hemophilia A that can affect joint health and structure (e.g., osteoarthritis) or with severely impaired mobility due to conditions other than hemophilia A
- Participants with known reduced bone mineral density defined as clinically relevant vitamin D deficiency
- Participants with pre-existing uncontrolled or unstable cardiovascular disease not receiving targeted medication or in a stable condition
- Participants not eligible for MRI
- History of illicit drug or alcohol abuse within 48 weeks prior to screening in the investigator's judgement
- Participants who are at high risk for thrombotic microangiopathy (TMA)
- Previous (within the last 12 months) or current treatment for thromboembolic disease (with the exception of previous catheter-associated thrombosis for which anti-thrombotic treatment is not currently ongoing) or signs of thromboembolic disease
- Other conditions (e.g., certain autoimmune diseases) that may currently increase the risk of bleeding or thrombosis
- History of clinically significant hypersensitivity associated with monoclonal antibody therapies or components of the emicizumab injection
- Planned surgery during the emicizumab loading dose phase
- Known HIV infection not controlled by medication
- Concomitant disease, condition, significant abnormality on screening evaluation or laboratory tests, or treatment that could interfere with the conduct of the study, or that would in the opinion of the investigator, pose an additional unacceptable risk in administering study drug to the participant
- Receipt of any of the following: An investigational drug to treat or reduce the risk of hemophilic bleeds within 5 half-lives of last drug administration at screening; A non-hemophilia-related investigational drug within last 30 days or 5 half-lives at screening, whichever is shorter; or, Any other investigational drug currently being administered or planned to be administered
- Inability to comply with the study protocol
- Pregnant or breastfeeding, or intending to become pregnant during the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1, Hemophilia A and Without Arthropathy: Emicizumab
Cohort 1 comprises participants with severe or moderate hemophilia A and with no synovitis and no osteochondral damage (Haemophilia Early Arthropathy Detection with Ultrasound [HEAD-US] score of 0) in all index joints.
|
The emicizumab dosing regimen will be 3 milligrams per kilogram of body weight (mg/kg) subcutaneously (SC) once a week (QW) for 4 weeks followed by participant preference of one of the following maintenance regimens: 1.5 mg/kg QW, 3 mg/kg once every 2 weeks (Q2W), or 6 mg/kg once every 4 weeks (Q4W) in agreement with the investigator.
Other Names:
|
Experimental: Cohort 2, Hemophilia A and with Synovitis Only: Emicizumab
Cohort 2 comprises participants with severe or moderate hemophilia A and with synovitis (HEAD-US synovitis score of ≥1) in at least one index joint and no osteochondral damage (HEAD-US bone and cartilage score of 0).
|
The emicizumab dosing regimen will be 3 milligrams per kilogram of body weight (mg/kg) subcutaneously (SC) once a week (QW) for 4 weeks followed by participant preference of one of the following maintenance regimens: 1.5 mg/kg QW, 3 mg/kg once every 2 weeks (Q2W), or 6 mg/kg once every 4 weeks (Q4W) in agreement with the investigator.
Other Names:
|
Experimental: Cohort 3, Hemophilia A and with Osteochondral Damage: Emicizumab
Cohort 3 comprises participants with severe or moderate hemophilia A and with osteochondral damage (HEAD-US bone and cartilage score of ≥1) in at least one index joint and with any synovitis score.
|
The emicizumab dosing regimen will be 3 milligrams per kilogram of body weight (mg/kg) subcutaneously (SC) once a week (QW) for 4 weeks followed by participant preference of one of the following maintenance regimens: 1.5 mg/kg QW, 3 mg/kg once every 2 weeks (Q2W), or 6 mg/kg once every 4 weeks (Q4W) in agreement with the investigator.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Joint Status at 6 Months, Based on Centrally Reviewed Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) Scores with a Specific Focus on the Synovitis Score in Participants with Synovitis
Time Frame: 6 Months
|
6 Months
|
|
Joint Status at 12 Months, Based on Centrally Reviewed Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) Scores with a Specific Focus on the Synovitis Score in Participants with Synovitis
Time Frame: 12 Months
|
12 Months
|
|
Joint Status at 24 Months, Based on Centrally Reviewed Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) Scores with a Specific Focus on the Synovitis Score in Participants with Synovitis
Time Frame: 24 Months
|
24 Months
|
|
Joint Status at 36 Months, Based on Centrally Reviewed Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) Scores with a Specific Focus on the Synovitis Score in Participants with Synovitis
Time Frame: 36 Months
|
36 Months
|
|
Clinical Joint Status at 6 Months, Based on the Hemophilia Joint Health Score (HJHS v2.1) Excluding Gait Assessment
Time Frame: 6 Months
|
6 Months
|
|
Clinical Joint Status at 12 Months, Based on the Hemophilia Joint Health Score (HJHS v2.1) Excluding Gait Assessment
Time Frame: 12 Months
|
12 Months
|
|
Clinical Joint Status at 24 Months, Based on the Hemophilia Joint Health Score (HJHS v2.1) Excluding Gait Assessment
Time Frame: 24 Months
|
24 Months
|
|
Clinical Joint Status at 36 Months, Based on the Hemophilia Joint Health Score (HJHS v2.1) Excluding Gait Assessment
Time Frame: 36 Months
|
36 Months
|
|
Joint Status at 36 Months, Based on Centrally Reviewed International Prophylaxis Study Group (IPSG) Score (with MRI)
Time Frame: 36 Months
|
36 Months
|
|
Number of Problem Joints at 6 Months
Time Frame: 6 Months
|
Problem joints are defined as joints having chronic joint pain and/or limited range of movement due to compromised joint integrity (i.e., chronic synovitis and/or hemophilic arthropathy) with or without persistent bleeding.
|
6 Months
|
Number of Problem Joints at 12 Months
Time Frame: 12 Months
|
Problem joints are defined as joints having chronic joint pain and/or limited range of movement due to compromised joint integrity (i.e., chronic synovitis and/or hemophilic arthropathy) with or without persistent bleeding.
|
12 Months
|
Number of Problem Joints at 24 Months
Time Frame: 24 Months
|
Problem joints are defined as joints having chronic joint pain and/or limited range of movement due to compromised joint integrity (i.e., chronic synovitis and/or hemophilic arthropathy) with or without persistent bleeding.
|
24 Months
|
Number of Problem Joints at 36 Months
Time Frame: 36 Months
|
Problem joints are defined as joints having chronic joint pain and/or limited range of movement due to compromised joint integrity (i.e., chronic synovitis and/or hemophilic arthropathy) with or without persistent bleeding.
|
36 Months
|
Percentage of Joints That are Problem Joints at 6 Months
Time Frame: 6 Months
|
6 Months
|
|
Percentage of Joints That are Problem Joints at 12 Months
Time Frame: 12 Months
|
12 Months
|
|
Percentage of Joints That are Problem Joints at 24 Months
Time Frame: 24 Months
|
24 Months
|
|
Percentage of Joints That are Problem Joints at 36 Months
Time Frame: 36 Months
|
36 Months
|
|
Change from Baseline in the CATCH Domain Scores Over Time, as Assessed with the Comprehensive Assessment Tool of Challenges in Hemophilia (CATCH) Questionnaire for Adult Participants
Time Frame: At Baseline (Day 1), Months 3, 6, 9, 12, 18, 24, 30, and 36
|
At Baseline (Day 1), Months 3, 6, 9, 12, 18, 24, 30, and 36
|
|
Change from Baseline in the CATCH Domain Scores Over Time, as Assessed with the CATCH Questionnaire for Pediatric Participants
Time Frame: At Baseline (Day 1), Months 3, 6, 9, 12, 18, 24, 30, and 36
|
At Baseline (Day 1), Months 3, 6, 9, 12, 18, 24, 30, and 36
|
|
Change from Baseline in the Average Daily Time Spent Doing Physical Activities by Intensity Level Over Time, as Assessed by Participant Responses to the International Physical Activity Questionnaire Short Format (IPAQ-SF)
Time Frame: At Baseline (Day 1), Months 3, 6, 9, 12, 18, 24, 30, and 36
|
At Baseline (Day 1), Months 3, 6, 9, 12, 18, 24, 30, and 36
|
|
Daily Step Count Over Time, as Measured with a Wearable Activity Tracker
Time Frame: From Baseline until end of treatment period (up to 36 months)
|
From Baseline until end of treatment period (up to 36 months)
|
|
Daily Metabolic Equivalents of Tasks (METs) Over Time, as Measured with a Wearable Activity Tracker
Time Frame: From Baseline until end of treatment period (up to 36 months)
|
From Baseline until end of treatment period (up to 36 months)
|
|
Daily Time Spent in Moderate to Vigorous Physical Activity (MVPA) Over Time, as per the Activity Tracker Default Categorization
Time Frame: From Baseline until end of treatment period (up to 36 months)
|
From Baseline until end of treatment period (up to 36 months)
|
|
Daily Active Minutes of Physical Activity Over Time, as Measured with a Wearable Activity Tracker
Time Frame: From Baseline until end of treatment period (up to 36 months)
|
From Baseline until end of treatment period (up to 36 months)
|
|
Model-Based Annualized Bleed Rates for All Bleeds, Treated Bleeds, Spontaneous Bleeds, Joint Bleeds, Treated Joint Bleeds, and Target Joint Bleeds
Time Frame: From Baseline until end of treatment period (up to 36 months)
|
From Baseline until end of treatment period (up to 36 months)
|
|
Mean Calculated Annualized Bleed Rates for All Bleeds, Treated Bleeds, Spontaneous Bleeds, Joint Bleeds, Treated Joint Bleeds, and Target Joint Bleeds
Time Frame: From Baseline until end of treatment period (up to 36 months)
|
From Baseline until end of treatment period (up to 36 months)
|
|
Median Calculated Annualized Bleed Rates for All Bleeds, Treated Bleeds, Spontaneous Bleeds, Joint Bleeds, Treated Joint Bleeds, and Target Joint Bleeds
Time Frame: From Baseline until end of treatment period (up to 36 months)
|
From Baseline until end of treatment period (up to 36 months)
|
|
Number of Participants who Prefer Emicizumab SC Treatment, Their Previous Hemophilia IV Treatment, or Have No Preference, as Assessed Through Use of the Emicizumab Preference Survey at Month 6
Time Frame: At Month 6
|
At Month 6
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants with at Least One Adverse Event, with Severity Determined According to the World Health Organization (WHO) Toxicity Scale
Time Frame: From Baseline until 24 weeks after the final dose of emicizumab (up to 3.5 years)
|
From Baseline until 24 weeks after the final dose of emicizumab (up to 3.5 years)
|
Number of Participants with at Least One Thromboembolic Event
Time Frame: From Baseline until 24 weeks after the final dose of emicizumab (up to 3.5 years)
|
From Baseline until 24 weeks after the final dose of emicizumab (up to 3.5 years)
|
Number of Participants with at Least One Event of Thrombotic Microangiopathy (TMA)
Time Frame: From Baseline until 24 weeks after the final dose of emicizumab (up to 3.5 years)
|
From Baseline until 24 weeks after the final dose of emicizumab (up to 3.5 years)
|
Number of Participants with at Least One Severe Hypersensitivity, Anaphylaxis, and Anaphylactoid Event
Time Frame: From Baseline until 24 weeks after the final dose of emicizumab (up to 3.5 years)
|
From Baseline until 24 weeks after the final dose of emicizumab (up to 3.5 years)
|
Number of Participants with at Least One Injection-Site Reaction
Time Frame: From Baseline until 24 weeks after the final dose of emicizumab (up to 3.5 years)
|
From Baseline until 24 weeks after the final dose of emicizumab (up to 3.5 years)
|
Number of Participants with Anti-Drug Antibodies (ADAs) Against Emicizumab at Baseline and During the Study
Time Frame: At Baseline, Months 6, 12, 24, and 36
|
At Baseline, Months 6, 12, 24, and 36
|
Number of Participants who Develop Anti-FVIII Inhibitors During the Study
Time Frame: At Months 6, 12, 24, and 36
|
At Months 6, 12, 24, and 36
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Clinical Trials, Hoffmann-La Roche
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MO42623
- 2020-005092-13 (EudraCT Number)
- 2023-505747-40-00 (Registry Identifier: EU CT Number)
- ISRCTN10101701 (Registry Identifier: ISRCTN)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
For eligible studies, qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/).
For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/innovation/process/clinical-trials/data-sharing/).
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Severe Hemophilia A
-
Christoph KönigsRoche Pharma AG; Chugai Pharma Germany GmbHRecruitingSevere Hemophilia A | Severe Hemophilia A With Inhibitor | Severe Hemophilia A Without InhibitorGermany
-
University College, LondonRecruiting
-
Kathelijn FischerRadboud University Medical Center; University Medical Center Groningen; Maastricht... and other collaboratorsRecruitingAdolescent | Child | Hemophilia A With Inhibitor | Adult | Hemophilia A Without Inhibitor | Hemophilia A, SevereNetherlands
-
Jiangsu Gensciences lnc.Not yet recruitingSevere Hemophilia AChina
-
Swedish Orphan BiovitrumSyneos HealthRecruitingHemophilia A, SevereItaly, Ireland, Belgium, Croatia, Greece, Spain, Sweden, Slovenia, United Kingdom, France, Germany, Norway, Austria, Czechia, Netherlands
-
Jiangsu Gensciences lnc.Completed
-
Jiangsu Gensciences lnc.Completed
-
CSL BehringCompletedHemophilia A | Severe Hemophilia AUnited States, Australia, Austria, Canada, Czechia, France, Georgia, Germany, Hungary, Ireland, Italy, Japan, Lebanon, Malaysia, Netherlands, Philippines, Poland, Portugal, Romania, South Africa, Spain, Switzerland, Thailand, Ukraine, United...
-
City of Hope Medical CenterCSL Behring; Grifols Therapeutics LLC; Grifols Biologicals, LLC; Charta Foundation and other collaboratorsWithdrawn
-
The Hospital for Sick ChildrenCompleted
Clinical Trials on Emicizumab
-
Hoffmann-La RocheCompletedHemophilia A | Healthy VolunteersChina
-
Kathelijn FischerRadboud University Medical Center; University Medical Center Groningen; Maastricht... and other collaboratorsRecruitingAdolescent | Child | Hemophilia A With Inhibitor | Adult | Hemophilia A Without Inhibitor | Hemophilia A, SevereNetherlands
-
Newark Beth Israel Medical CenterGenentech, Inc.Not yet recruiting
-
Chulalongkorn UniversityRecruitingComparison of Outcomes Between Low Dose Emicizumab and Factor VIII in Clinically Severe Hemophilia AJoint Bleed | Severe Hemophilia A Without InhibitorThailand
-
Indiana Hemophilia &Thrombosis Center, Inc.Genentech, Inc.Terminated
-
Children's Hospital Los AngelesGrifols Biologicals, LLCActive, not recruitingHemophilia A | Immune ToleranceUnited States
-
Bleeding and Clotting Disorders Institute Peoria...Genentech, Inc.RecruitingVon Willebrand Disease, Type 3 | Concomitant VWD and HemophiliaUnited States
-
Wayne State UniversityGenentech, Inc.Recruiting
-
Indiana Hemophilia &Thrombosis Center, Inc.Genentech, Inc.Recruiting
-
University of WashingtonGenentech, Inc.Recruiting